Monokine production by hypersensitivity (Schistosoma mansoni egg) and foreign body (Sephadex bead)-type granuloma macrophages. Evidence for sequential production of IL-1 and tumor necrosis factor.
The present study examined the potential role of IL-1 and TNF in granuloma formation. Mice were given i.v. injections of Schistosoma mansoni eggs or Sephadex beads to induce synchronous immune T cell-mediated (hypersensitivity type) or nonimmune (foreign-body type) granulomas, respectively. Granuloma macrophages isolated at 2, 4, 8, 16, and 32 days of granuloma formation were evaluated for their capacity to produce IL-1 and TNF in response to 1 microgram/ml LPS. This was related to circulating levels of the acute phase protein, serum amyloid P (SAP) and expression of Ia Ag by monocytes and macrophages. Macrophages from nonimmune bead lesions were generally weak producers of IL-1 and TNF. In contrast, those from T cell-mediated egg lesions produced significant levels of both monokines. Moreover, there was a clear pattern of sequential monokine production such that IL-1 was produced in greatest amounts early (2 to 4 days), whereas TNF was produced later (8 to 16 days). Levels of SAP showed an initial sharp rise following particle embolization, then decreased rapidly in bead injected animals. However, mice with immune granulomas showed a prolonged elevation in SAP levels that corresponded to the period of maximal IL-1 production (2 to 4 days). Macrophage/monocyte Ia Ag expression was greatest at 8 to 16 days, corresponding to the period of TNF production. Bead injected animals showed low levels of Ia expression over the study period. These findings suggest that IL-1 may be important in the early recruitment stages of granuloma formation while TNF may take part in later maintenance or effector functions. The extent of production of both is likely influenced by the local or systemic milieu of lymphokines.
Chensue
S W
SW
Department of Pathology, Veterans Administration Medical Center, Ann Arbor, MI 48105.
Otterness
I G
IG
Higashi
G I
GI
Forsch
C S
CS
Kunkel
S L
SL
D000210:Acute-Phase Reaction / Q000097:blood; D000818:Animals; D000947:Antigens, Helminth / Q000008:administration & dosage*; D003911:Dextrans / Q000008:administration & dosage*; D005260:Female; D006099:Granuloma / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006967:Hypersensitivity / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D007375:Interleukin-1 / Q000096:biosynthesis*; D008174:Lung Diseases, Parasitic / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000032:analysis / Q000378:metabolism*; D051379:Mice; D008808:Mice, Inbred CBA; D008863:Microspheres; D009000:Monocytes / Q000032:analysis; D010063:Ovum / Q000276:immunology; D000685:Serum Amyloid A Protein / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D000947:Antigens, Helminth; D003911:Dextrans; D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; C025614:sephadex